SELLAS Life Sciences Group, Inc. (SLS)

SLS Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	1	7.6	1.9
Revenue Growth (YoY)	-	-	-86.84%	300.00%	-
Cost of Revenue	-	-	0.1	0.2	-
Gross Profit	-	-	0.9	7.4	1.9
Selling, General & Admin	12.42	13.86	12.58	11.32	9.6
Research & Development	19.1	24.01	20.27	15.67	9.28
Operating Expenses	31.51	37.87	32.85	26.99	18.88
Operating Income	-31.51	-37.87	-31.95	-19.59	-16.98
Interest & Investment Income	0.63	0.53	0.32	0.01	0.03
Other Non Operating Income (Expenses)	-	0	0.04	0.02	-0.1
EBT Excluding Unusual Items	-30.88	-37.34	-31.6	-19.57	-17.05
Other Unusual Items	-	-	0.3	4.34	0.28
Pretax Income	-30.88	-37.34	-41.3	-20.94	-16.77
Income Tax Expense	-	-	-	-0.24	-0.02
Net Income	-30.88	-37.34	-41.3	-20.7	-16.76
Preferred Dividends & Other Adjustments	-	-	-	-	0.08
Net Income to Common	-30.88	-37.34	-41.3	-20.7	-16.84
Shares Outstanding (Basic)	61	28	19	15	8
Shares Outstanding (Diluted)	61	28	19	15	8
Shares Change (YoY)	120.33%	43.21%	25.29%	94.07%	211.76%
EPS (Basic)	-0.50	-1.34	-2.13	-1.34	-2.11
EPS (Diluted)	-0.50	-1.34	-2.13	-1.34	-2.11
Free Cash Flow	-35.4	-31.41	-23.81	-26.02	-10.42
Free Cash Flow Per Share	-0.58	-1.13	-1.23	-1.68	-1.31
Gross Margin	-	-	90.00%	97.37%	100.00%
Operating Margin	-	-	-3195.00%	-257.82%	-893.79%
Profit Margin	-	-	-4130.10%	-272.36%	-886.05%
Free Cash Flow Margin	-	-	-2380.90%	-342.38%	-548.26%
EBIT	-31.51	-37.87	-31.95	-19.59	-16.98
EBIT Margin	-	-	-	-257.82%	-

Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q